Adverse events associated with prolonged antibiotic use

Pharmacoepidemiology and Drug Safety

Volumn 17, Issue 5, 2008, Pages 523-532

  Meropol, Sharon B ^a   Chan, K Arnold ^b   Chen, Zhen ^a   Finkelstein, Jonathan A ^c,d   Hennessy, Sean ^a   Lautenbach, Ebbing ^a   Platt, Richard ^c,d   Schech, Stephanie D ^e   Shatin, Deborah ^e   Metlay, Joshua P ^a,f  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d HARVARD PILGRIM HEALTH CARE   (United States)

^e Center for Health Care Policy and Evaluation   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Anthrax prevention and Control; Anti infective agents; Bioterrorism; Databases; Health services research

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; CIPROFLOXACIN; DOXYCYCLINE;

ADOLESCENT; ADULT; AGED; ANAPHYLAXIS; ANTHRAX; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CHILD; COLITIS; CONSULTATION; CONTROLLED STUDY; DATA BASE; DRUG EXPOSURE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG USE; ELECTRONIC MEDICAL RECORD; FEMALE; HEALTH CARE ORGANIZATION; HEART VENTRICLE ARRHYTHMIA; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INCIDENCE; INFANT; LIVER TOXICITY; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PHOTOTOXICITY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PSEUDOMEMBRANOUS COLITIS; RANDOM SAMPLE; RISK ASSESSMENT; SEIZURE;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AMOXICILLIN; ANTHRAX; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; CHILD; CHILD, PRESCHOOL; CIPROFLOXACIN; COHORT STUDIES; DATABASES, FACTUAL; DOXYCYCLINE; FEMALE; HOSPITALIZATION; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK ASSESSMENT; TIME FACTORS;

EID: 44249087163     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1547     Document Type: Article

References (31)

1. Recommendations for Postexposure Prophylaxis for Prevention Of Inhalational Anthrax Following Exposure to Bacillis anthracis. http://www.cidrap.umn.edu/cidrap/files/17/anthrax-clinical-pathway.pdf [Accessed 19 June 20061.
2. Bush L, Malecki J, Wiersma S, et al. Investigation of anthrax associated with intentional exposure and interim public health guidelines. Centers for Disease Control and Prevention, October 2001. MMWR Morb Mortal Wkly Rep 2001; 50(41): 889-893.
3. Centers for Disease Control and Prevention. Interim recommendations for antimicrobial prophylaxis for children and breastfeeding mothers and treatment of children with anthrax. MMWR Morb Mortal Wkly Rep 2001; 50(45):1014-1016.
4. Budnitz DS, Pollock DA, Weidenbach KN, Mendelsohn AB, Schroeder TJ, Annest JL. National surveillance of emergency department visits for outpatient adverse drug events. JAMA 2006; 296(15): 1858-1866.
5. Schwartz DB. Community-acquired pneumonia-optimizing antibiotic usage. Curr Opin Pulm Med 2004; 10(Suppl. 1): S4-S8.
6. Dowell SF, Marcy SM, Phillips WR, Gerber MA, Schwartz BOtitis. Media - principles of judicious use of antimicrobial agents. Pediatrics 1998; 101(1): 165-171.
7. Henry DA, Gettigan PM, Tonkin A, Hennessy S. Basic principles of clinical pharmacology relevant to pharmacoepidemiology studies. In Pharmacoepidemiology (4th edn), Strom B (ed.). John Wiley & Sons, Ltd: West Sussex, UK, 2005; 38.
8. Guess HA. Exposure-time-varying hazard function ratios in case-control studies of drug effects. Pharmacoepidemiol Drug Saf 2006; 15(2): 81-92.
9. Moride Y, Abenhaim L. Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research. J Clin Epidemiol 1994; 47(7): 731-737.
10. Centers for Disease Control and Prevention. Investigation of bioterrorism-related anthrax and adverse events from antimicrobial prophylaxis. MMWR Morb Mortal Wkly Rep 2001; 50(44): 973-976.
11. Quentzel H, Spear S, Barakat L, et al. Adverse events associated with anthrax prophylaxis among postal employees - New Jersey, New York City, and the District of Columbia metropolitan area. Centers for Disease Control and Prevention, 2001. MMWR Morb Mortal Wkly Rep 2001; 50(47): 1051-1054.
12. Code of Federal Regulations-Reporting of Adverse Experiences, 21 CFR 600.80. Code of Federal Regulations [Revised 1 April 2001; 21 CFR 600.80] http://a257.g.akamaitech.net/7/257/2422/04nov20031500/ edocket.access.gpo.gov/cfr_2001/aprqtr/pdf/21cfr600.80.pdf [Accessed 29 November 2006].
13. Hennessy S, Bilker WB, Zhou L, et al. Retrospective drug utilization review, prescribing errors, and clinical outcomes. JAMA 2003; 290(11): 1494-1499.
14. Ray WA. Population-based studies of adverse drug effects. N Engl J Med 2003; 349(17): 1592-1594.
15. Segev S, Yaniv I, Haverstock D, Reinhart H. Safety of long-term therapy with ciprofloxacin: data analysis of controlled clinical trials and review. Clin Infect Dis 1999; 28(2): 299-308.
16. Ahmad S, Goetsch RA, Marks NS. Spontaneous reporting in the United States. In Pharmacoepidemiology (4th edn), Strom BL (ed.). John Wiley & Sons: West Sussex, UK 2005.
17. Begaud B, Moride Y, Tubert-Bitter P, Chaslerie A, Haramburu F. False-positives in spontaneous reporting: should we worry about them? Br J Clin Pharmacol 1994; 38(5): 401-404.
18. Strom BL (ed.). Overview of automated databases in pharmacoepidemiology. In Pharmacoepidemiology. John Wiley & Sons, Ltd.: West Sussex, UK, 2005; 219-222.
19. GPRD, Excellence in Public Health Research: the Gold Standard of Healthcare Data from Primary Care. http://www.gprd.com/whygprd/ goldstandard.asp [Accessed 17 March 2006].
20. GPRD, Excellence in Public Health Research: Using GPRD for Primary Care Research. http://www.gprd.com/academia/infogprd.asp [Accessed 17 March 2006].
21. GPRD, Excellence in Public Health Research: Facts and Figures. http://www.gprd.com/whygprd/factsandfigures.asp [Accessed 17 March 2006].
22. Metlay JP, Kinman J. Failure to validate pneumococcal pneumonia diagnoses in the General Practice Research database. Pharmacoepidemiol Drug Saf 2003; 12: S163. [abstract].
23. Hollowell J. The General Practice Research Database: quality of morbidity data. Popul Trends 1997; 87: 36-40.
24. Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. Br Med J 1991; 302(6779): 766-768.
25. Shatin D, Rawson NSB, Stergachis A. UnitedHealth group. In Pharmacoepidemiology (4th edn), Strom BL (ed.), John Wiley & Sons, Ltd.: West Sussex, UK, 2005.
26. Chan K, Davis RL, Gunter MJ, et al. The HMO Research Network In Pharmacoepidemiology (4th edn), Strom BL (ed.). John Wiley & Sons, Ltd.: West Sussex, UK, 2005.
27. Platt R, Kleinman K, Thompson K, et al. Using automated health plan data to assess infection risk from coronary artery bypass surgery. Emerg Infect Dis 2002; 8(12): 1433-1441.
28. Miettinen OS, Caro JJ. Principles of nonexperimental assessment of excess risk, with special reference to adverse drug reactions. J Clin Epidemiol 1999; 42(4): 325-331.
29. McMahon AD, Evans JM, McGilchrist MM, McDevitt DG, MacDonald TM. Drug exposure risk windows and unexposed comparator groups for cohort studies in pharmacoepidemiology. Pharmacoepidemiol Drug Saf 1998; 7(4): 275-280.
30. Cox D. Some simple approximate tests for Poisson variates. Biometrika 1953; 40(3/4): 354-360.
31. Nilsson J, Johansson H, Wennberg M. Large differences between prescribed and dispensed medicines could indicate undertreatment. Drug Inf J 1995; 29: 1243-1246.